NewCelX

Company Overview

Snapshot

Founded in October 2008 by Michel Revel, NewCelX operates with 11–50 employees. The company has raised over $45.35 million across 9 funding rounds from 11 investors. In October 2025, NewCelX completed a merger with NLS Pharmaceutics Ltd. and began trading on NASDAQ.

Business overview

NewCelX is a biotechnology company focused on developing innovative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. Leveraging advanced stem-cell technologies and neuroscience expertise, the company's integrated platform aims to deliver scalable, regenerative treatments. NewCelX primarily targets conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes, operating within the Health Tech & Life Sciences sector.

Strategic signal

In October 2025, NewCelX completed its merger with NLS Pharmaceutics Ltd. and commenced trading on NASDAQ. This strategic move signals a significant expansion of NewCelX's operational capabilities and market reach, positioning the combined entity to accelerate the development and commercialization of its cell-based and small-molecule therapies. For investors, this merger and public listing indicate a maturation of the company's business model and a pathway for increased capital access and liquidity.

Company Intelligence Q&A

What was a significant corporate development for NewCelX in late 2025?

In October 2025, NewCelX completed its merger with NLS Pharmaceutics Ltd. and subsequently began trading on NASDAQ.

What was the outcome of the shareholder vote regarding the merger with NLS Pharmaceutics?

In September 2025, NLS Pharmaceutics shareholders approved the merger with Kadimastem (now NewCelX) and related proposals at an Extraordinary General Meeting.

Did NewCelX receive any recent patent approvals for its diabetes treatment technology?

In September 2025, NewCelX (formerly Kadimastem) and NLS Pharmaceutics announced a Hong Kong patent covering cell-selection and enrichment technology for IsletRx, intended for diabetes patients.

What was the purpose of the SEC registration statement announced in September 2025?

In September 2025, Kadimastem (now NewCelX) and NLS Pharmaceutics announced the effectiveness of an SEC registration statement in connection with their proposed merger.

What was a key regulatory submission made by NewCelX in May 2026?

In May 2026, NewCelX Ltd. submitted a Pre-IND Package to the FDA for NCEL-101, a treatment for Type 1 Diabetes.